Printer Friendly

GYNEX ANNOUNCES CONTRACEPTIVE LICENSE AGREEMENT WITH ORGANON

 VERNON HILLS, Ill., Jan. 13 /PRNewswire/ -- Gynex Pharmaceuticals Inc. (NASDAQ: GYNX) today announced it granted a license to a company of the Organon Group for Gynex's patented dosage regimen for oral contraceptives. The agreement came as Organon exercised a previous option arrangement, after successfully concluding a human clinical trial to determine the efficacy and potential superiority of Gynex's regimen. Organon is part of Akzo Pharma, a division of Akzo of the Netherlands (NASDAQ: AKZOY).
 Payments Potential Royalties for Gynex
 Gynex received a $175,000 payment from Organon when the license agreement was signed. Pending successful development of the oral contraceptive by Organon, additional payments of up to $275,000 for rights in the United States and up to $500,000 for international markets will be made. An advance royalty payment of $250,000 also will be paid to Gynex at the time of U.S. Food and Drug Administration (FDA) approval to market. In addition, royalties on product sales will be paid to Gynex by Organon.
 Stephen M. Simes, Gynex president, said, "Based on the results of the clinical trial, we expect Organon will pursue diligently development of our patented dosing regimen. If Organon ultimately develops and markets a new oral contraceptive, the royalties to Gynex could be substantial."
 Organon: Worldwide Leader in Oral Contraceptives
 Organon presently markets Marvelon, the leading oral contraceptive in the world, which was recently approved in the United States under the Desogen trademark. It also is active in the $1 billion U.S. oral contraceptive market through a co-development and marketing agreement with Ortho Pharmaceutical Corp., a subsidiary of Johnson and Johnson.
 Ortho presently markets the leading oral contraceptive in the United States.
 Second Agreement Under Gynex Patent
 Oral contraceptives use different combinations of estrogen and progestogens, as well as various dosing regimens. Gynex's patent uses a unique dosing regimen, which may be combined with a variety of progestogens.
 This license agreement -- the second for Gynex under this patent -- is limited to Organon's present and future progestogens. The other agreement, with Bristol-Myers Squibb, is limited to the progestogen in that company's marketed oral contraceptives. Therefore, Gynex is free to pursue licenses with other companies for other progestogens.
 Gynex Pharmaceuticals Inc. develops and markets products for use in endocrinology, urology, metabolism, AIDS and gynecology.
 Akzo is a worldwide group of companies with operations in 50 countries. Its product range includes chemical products, fibers, coatings and health care products.
 -0- 1/13/93
 /CONTACT: Stephen Simes of Gynex, 708-913-1144; or Lynne Franklin of The Financial Relations Board, 312-266-7800, for Gynex/
 (GYNX AKZOY)


CO: Gynex Pharmaceuticals Inc.; Organon Group; Akzo Pharma ST: Illinois IN: MTC SU: LIC

BP-JL -- LA011 -- 4459 01/13/93 11:54 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 13, 1993
Words:448
Previous Article:ARCO TO SPEND $7 MILLION FOR NEW PROJECTS FOCUSING ON JOBS, BUSINESS DEVELOPMENT, REVITALIZING INNER CITY LOS ANGELES
Next Article:CARLSON HOSPITALITY GROUP, INC. AND HOSPITALITY FRANCHISE SYSTEMS, INC. ANNOUNCE STRATEGIC ALLIANCE
Topics:


Related Articles
WORLD'S MOST PRESCRIBED ORAL CONTRACEPTIVE, DESOGEN, NOW AVAILABLE IN U.S.
GYNEX PHARMACEUTICALS AND BIO-TECHNOLOGY GENERAL AGREE TO MERGE
FIRST NATIONWIDE SEX EDUCATION PROGRAM FOR PARENTS IS LAUNCHED BY ORGANON
MISINFORMATION ABOUT BIRTH CONTROL PILLS IS WIDESPREAD, DESPITE HIGH PREVALENCE OF USE
NEARLY 700,000 UNPLANNED PREGNANCIES PREVENTABLE WITH IMPROVED USE OF BIRTH CONTROL PILLS
Organon Receives FDA Approval to Market MIRCETTE(TM)
MIRCETTE(TM), Newest Low-Dose Oral Contraceptive, Now Available For Prescription
Organon's Once-a-Month Contraceptive Ring, NuvaRing(R) Completes European Authorization.
FDA approves single-rod contraceptive implant.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters